May 10, 2022 / 11:40PM GMT
Derik De Bruin - BofA Securities, Research Division - MD of Equity Research
Good afternoon, everyone. Welcome to the 2022 Bank of America Healthcare Conference, live from beautiful Las Vegas. Nice to see everybody here. I'm Derik De Bruin, the Senior Life Sciences and Diagnostic Tools Analyst for Bank of America. And now for something completely different, let's talk proteomics, here we are today with Seer. And with us from Seer is Chief Executive Officer and Founder, Omid Farokhzad, and CFO, David Horn. Gentlemen, thank you for being here. Thank you for coming in to be with us today.
Questions and Answers:
Derik De Bruin - BofA Securities, Research Division - MD of Equity ResearchSo start off with the question and we were just chatting about this. You guys were the first proteomics company to go public, and then there was this wave of other companies that went public. And I think one of the questions I get from investors is, how do you sort of differentiate all these companies? So can you sort of put Seer in the competitive landscape and sort of would